Abstract | PURPOSE: MATERIALS AND METHODS: The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous alpha-blockers. Subjects were randomized to receive terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less ("delighted-to-mostly satisfied") on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects. RESULTS: Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the terazosin group compared to 14 of 43 (36%) in the placebo group (p = 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the terazosin group compared to 16 of 43 (37%) in the placebo group (p = 0.03). The terazosin group had greater reductions (p <0.05) in NIH-CPSI total score, individual domain scores and International Prostate Symptom Score than the placebo group. There was no difference in peak urinary flow rate or post-void residual. In the terazosin group 18 patients (42%) had side effects compared to 9 (21%) in the placebo group (p = 0.04). CONCLUSIONS:
|
Authors | Phaik Yeong Cheah, Men Long Liong, Kah Hay Yuen, Chu Leong Teh, Timothy Khor, Jin Rong Yang, Hin Wai Yap, John N Krieger |
Journal | The Journal of urology
(J Urol)
Vol. 169
Issue 2
Pg. 592-6
(Feb 2003)
ISSN: 0022-5347 [Print] United States |
PMID | 12544314
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Terazosin
- Prazosin
|
Topics |
- Adrenergic alpha-Antagonists
(therapeutic use)
- Adult
- Chronic Disease
- Humans
- Male
- Middle Aged
- Pelvic Pain
(drug therapy, etiology)
- Prazosin
(analogs & derivatives, therapeutic use)
- Prostatitis
(complications, drug therapy)
- Syndrome
|